诺泰生物：持续深耕生物制药新质生产力赛道

Core Insights - Jiangsu Nuotai Aosaino Biopharmaceutical Co., Ltd. has been selected as a "National Intellectual Property Demonstration Enterprise" by the National Intellectual Property Administration [1] - The company has made significant breakthroughs in multiple fields, including peptide drugs and oligonucleotides, establishing itself as a representative of new productive forces in biopharmaceuticals [1] Group 1: Company Achievements - As a national-level specialized and innovative "little giant" enterprise, Nuotai Biopharmaceutical adheres to a research-driven strategy, having applied for a total of 230 patents, including 191 invention patents, with 72 already granted [1] - The company has developed a large-scale production technology platform for long-chain peptide drugs, achieving single-batch production of over 10 kilograms for drugs like Semaglutide and Teriparatide [1] Group 2: Production Capacity and Market Expansion - Nuotai Biopharmaceutical is set to complete the construction of its oligonucleotide commercial production workshop by 2025, with an annual capacity of 1,000 kilograms for oligonucleotides, 100 kilograms for PMO, and 200 kilograms for PEG-conjugated cyclic peptides [1] - The company has established solid partnerships with leading generic and innovative pharmaceutical companies, with a significant contract worth approximately $20 million for 2025, exceeding the initial procurement guidance [2] Group 3: Future Vision - The company aims to contribute to the high-quality development of the pharmaceutical industry and the construction of a healthy China, with a commitment to becoming a century-old enterprise [2]